glp 1 agonists on the market GLP-1 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Agonists Market Exclusive Research

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Learn what retatrutide does and how it affects appetite, blood sugar and energy use

Supports a gut environment where GLP-1 thrives*: Eriomin and Feiolix promote a healthy metabolic environment by supporting gut health and maintaining balanced oxidative stress and inflammation responses.

Agents that agonize glucagon-like peptide 1 receptors, including those that co-agonize other anorexigenic hormone receptors, lead to substantial weight loss and benefits in people with varying obesity-related complications, with further trials underway

Propensity score fine stratification weighted Cox proportional hazards models were fitted to estimate hazard ratios and 95% confidence intervals (CIs) to estimate the average treatment effect among the treated patients

Important conclusions drawn from recent meta-analyses involving over 300,000 patients report that while the retained gastric contents are significantly increased (fivefold to tenfold increase